The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News